Similar Papers

Paper Title
Journal
Date
Author
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions
Kenichi Umehara ... Felix Huth
Drug Metabolism and Personalized Therapy | VOL. 34
Kenichi Umehara, et. al.Kenichi Umehara ... Felix Huth
30 May 2019
Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision-making-A workshop summary.
Daphney Jean ...
CPT: Pharmacometrics & Systems Pharmacology | VOL. 10
Daphney Jean, et. al.Daphney Jean ...
18 Sep 2021
PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management.
Bárbara Costa ... Nuno Vale
Pharmaceutics | VOL. 16
Bárbara Costa, et. al.Bárbara Costa ... Nuno Vale
03 Sep 2024
Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
Felix Stader ... Catia Marzolini
Clinical Pharmacology & Therapeutics | VOL. 110
Felix Stader, et. al.Felix Stader ... Catia Marzolini
29 Mar 2021
View more papers

More From: Drug metabolism and disposition: the biological fate of chemicals

Paper Title
Journal
Date
Author
Erratum to "After 50 Years of Hepatic Clearance Models, Where Should We Go from Here? Improvements and Implications for Physiologically Based Pharmacokinetic Modeling".
-
Drug metabolism and disposition: the biological fate of chemicals | VOL. 53
--
01 May 2025
Characterization of intestinal transporters in human ileal spheroid-derived differentiated cells for the prediction of intestinal drug absorption.
Kazuyoshi Michiba ... Hiroyuki Kusuhara
Drug metabolism and disposition: the biological fate of chemicals | VOL. 53
Kazuyoshi Michiba, et. al.Kazuyoshi Michiba ... Hiroyuki Kusuhara
01 May 2025
Coproporphyrin I as an invitro fluorescent probe to measure OATP1B1 transport activity.
Elizabeth R Hayden ... Jason A Sprowl
Drug metabolism and disposition: the biological fate of chemicals | VOL. 53
Elizabeth R Hayden, et. al.Elizabeth R Hayden ... Jason A Sprowl
01 May 2025
Erlotinib-A substrate and inhibitor of OATP2B1: pharmacokinetics and CYP3A-mediated metabolism in rSlco2b1-/- and SLCO2B1+/+ rats.
Marta A Rysz ... Henriette E Meyer Zu Schwabedissen
Drug metabolism and disposition: the biological fate of chemicals | VOL. 53
Marta A Rysz, et. al.Marta A Rysz ... Henriette E Meyer Zu Schwabedissen
01 May 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.